Early Post-Transplant Complications

Early post-transplant complications — most commonly defined as occurring within 30–90 days of surgery, though the majority of life-threatening events declare themselves in the first two weeks — fall into three mechanistic categories: vascular (arterial, venous outflow, portal), biliary, and parenchymal/hemodynamic (including small-for-size syndrome (SFSS)).

Biochemical patterns to recognize

• Steep AST/ALT rise (>1,000 U/L): vascular cause until proven otherwise — hepatic artery thrombosis (HAT), portal vein thrombosis (PVT), or severe outflow obstruction causing hepatocyte ischemia
• Cholestatic pattern (ALP/GGT and bilirubin dominant): biliary complication — leak, anastomotic stricture, or ischemic cholangiopathy (IC). Also seen in graft outflow obstruction producing sinusoidal congestion.
• Persistent hyperbilirubinemia + coagulopathy + refractory ascites, POD 1–7: SFSS in living-donor liver transplantation (LDLT) or split-liver recipients

Doppler surveillance

Duplex doppler ultrasound is the cornerstone of early post-transplant monitoring. Most programs perform it within 2–6 hours of graft reperfusion in the OR or ICU, then daily for the first week.

Complication comparison at a glance

The five major early complications, organized by the axes that distinguish them — onset window, the doppler signature, and the first move:

T-tube — what it is and why it matters

Some transplant centers place a T-tube at the bile duct anastomosis. A T-tube is a soft latex or rubber drain shaped like the letter T: the horizontal bar sits inside the common bile duct spanning the anastomosis; the vertical stem exits through the abdominal wall. It decompresses the anastomosis, allows external bile drainage, and provides direct access for a cholangiogram (contrast imaging of the bile duct anatomy) to assess anastomotic healing. Most centers remove the T-tube 3–6 months post-transplant. Not all centers use T-tubes routinely; randomized evidence on their benefit is mixed.

Bile leak

• Sources: the biliary anastomosis (duct-to-duct or hepaticojejunostomy), T-tube exit site after early or traumatic removal, or the cut liver surface in split-liver or LDLT
• Presentation: bilious output from abdominal drains, fever, rising ALP/GGT and bilirubin, and peritonitis if bile pools intraperitoneally
• Diagnosis: MRCP (magnetic resonance cholangiopancreatography) or endoscopic retrograde cholangiopancreatography (ERCP) / percutaneous cholangiogram
• Management: anastomotic leaks — ERCP + biliary stenting (first-line, 80–90% success); large or surgically complex leaks — operative revision. T-tube site leaks after early removal — ERCP ± stenting.

Anastomotic stricture (AS)

A focal narrowing at the biliary anastomosis, typically ischemic or technical in origin. Responds well to ERCP + balloon dilation ± stenting, with initial success in ~57% in systematic review data (Akamatsu et al., Transpl Int 2011, PMID 21143651); repeat dilation courses improve long-term success. Clinically and radiologically distinct from the diffuse, biliary tree–wide injury of ischemic cholangiopathy.

Ischemic cholangiopathy (IC)

IC is characterized by diffuse, non-anastomotic biliary strictures affecting the intrahepatic and/or extrahepatic bile ducts. The cholangiocytes (biliary epithelial cells) rely exclusively on the hepatic artery for their blood supply through the peribiliary vascular plexus — they receive no meaningful oxygen from the portal circulation. This makes the biliary epithelium uniquely vulnerable to any arterial insult.

• Risk factors: donation after circulatory death (DCD) donors (warm ischemia exposure before procurement), prolonged cold ischemia time (>8–10 hours), late or silent HAT, and severe ischemia-reperfusion injury at reperfusion
• Presentation: cholestatic liver enzymes weeks to months post-transplant, recurrent episodes of cholangitis, and biliary sepsis
• Diagnosis: MRCP — irregular, multifocal intrahepatic strictures, often with proximal ductal dilation; hepatic venography or liver biopsy may support the diagnosis
• Management: endoscopic or percutaneous dilation of dominant strictures reduces cholangitis episodes; approximately 40–50% ultimately require retransplantation because diffuse biliary destruction is irreversible

Hepatic artery thrombosis (HAT)

HAT is the most feared early vascular complication after liver transplantation. The hepatic artery provides the sole blood supply to the biliary epithelium, so thrombosis causes not only hepatocyte ischemia but rapid biliary tree necrosis — even if the hepatocytes survive transiently on portal oxygen.

• Incidence: approximately 2.9% in adults and 8.3% in children (Bekker et al., systematic review of 71 studies, PMID 19298450); overall incidence ~4.4%; higher in LDLT (smaller vessel caliber, more complex arterial reconstruction)
• Presentation: massive transaminase elevation (often >1,000 U/L), fever, sepsis, bile leak, and biloma formation; occasionally detected silently on routine surveillance doppler before clinical signs emerge
• Diagnosis: duplex doppler ultrasound is first-line (sensitivity >90% for early HAT); CT angiography is performed to confirm and define anatomy before surgery

Timing determines management

• Early HAT (<2 weeks): surgical emergency. Emergency thrombectomy ± revascularization if identified within hours of thrombosis; a functioning graft can sometimes be preserved. If the graft is already ischemic and non-viable: emergency relisting for retransplantation.
• Late HAT (>2 weeks): often presents insidiously as ischemic cholangiopathy or recurrent biliary sepsis weeks after surgery. Management is guided by residual hepatic synthetic function; retransplantation is frequently required.

Hepatic artery stenosis (HAS)

Partial narrowing of the hepatic artery is less immediately catastrophic than thrombosis but represents a significant risk factor for progression to HAT if untreated. Doppler findings: elevated peak systolic velocity at the stenotic segment, post-stenotic turbulence, and a tardus-parvus waveform pattern distally — a delayed systolic upstroke and reduced pulsatility index reflecting the pressure drop across the stenosis.

Management: percutaneous transluminal angioplasty (PTA) ± stent placement; surgical revision of the anastomosis if endovascular therapy fails.

Hepatic venous outflow obstruction occurs most often after the piggyback technique of liver transplantation — in which the recipient's inferior vena cava (IVC) is preserved intact and the donor hepatic veins are anastomosed to the recipient's hepatic vein confluence or directly to the IVC. Stenosis at this anastomosis impairs venous drainage from the graft, causing hepatic congestion.

Presentation

The picture resembles Budd-Chiari syndrome:

• Progressive, disproportionate ascites
• Hepatomegaly and graft tenderness
• Lower extremity edema if the IVC is significantly compressed
• Cholestatic liver enzymes; declining synthetic function in severe or prolonged cases

Diagnosis

• Duplex doppler ultrasound: loss of the normal triphasic hepatic vein waveform (replaced by a biphasic or flat/monophasic pattern); elevated peak velocity across the anastomotic stenosis
• Hepatic venography: gold standard — directly measures the pressure gradient across the anastomosis. A gradient >3–5 mmHg is clinically significant.
• CT or MR venography: defines anatomy and helps plan the percutaneous approach

Management

Percutaneous transluminal angioplasty (PTA) with or without stent placement is first-line treatment. Technical success — defined as a post-procedure pressure gradient ≤3 mmHg — is achievable in nearly all anatomically accessible cases. Surgical revision of the anastomosis is reserved for failures of endovascular therapy.

Portal vein thrombosis (PVT) after transplant

Post-transplant PVT is less common than HAT but can produce rapid graft decompensation. Risk factors include pre-existing PVT at the time of transplantation, technically difficult portal vein reconstruction, a small or fibrotic recipient portal vein, and underlying hypercoagulable states.

• Presentation: graft congestion, acute new-onset ascites, variceal bleeding, and rising portal pressure; duplex doppler ultrasound reveals absent portal vein flow or reversal of flow direction
• Management: systemic anticoagulation with heparin (if the graft is viable and there is no active bleeding), surgical thrombectomy, or catheter-directed thrombolysis. Retransplantation if the graft is non-viable.

Small-for-size syndrome (SFSS)

SFSS occurs when the transplanted graft is too small for the recipient's metabolic needs and portal blood flow. It is most relevant in living-donor liver transplantation (LDLT) and split-liver transplantation. The widely used risk threshold is a graft-to-recipient weight ratio (GRWR) <0.8%, or a graft volume <30–35% of the recipient's standard liver volume (SLV) — the predicted volume for a person of that height and weight.

Pathophysiology

An undersized graft receives the same portal blood flow as a full-size liver — flow that its smaller sinusoidal volume cannot accommodate. This portal hyperperfusion generates sinusoidal hypertension, endothelial shear stress, and microvascular injury, impairing the graft's ability to regenerate and function. The problem is compounded in cirrhotic recipients who already have a hyperdynamic portal circulation and elevated portal pressures pre-transplant.

Presentation

• Persistent hyperbilirubinemia and coagulopathy beginning POD 1–5
• Refractory ascites despite diuretics
• Encephalopathy out of proportion to other findings
• Diagnosis of exclusion: HAT, biliary obstruction, acute rejection, and sepsis must each be excluded before attributing the picture to SFSS

Management

• Portal flow modulation: reduce sinusoidal pressure by limiting portal inflow — options include splenic artery ligation or embolization, splenectomy, or a hemiportocaval shunt
• Prevention: target GRWR ≥0.8% during donor selection; measure intraoperative portal pressure and consider flow modulation prophylactically if pressure is elevated